Cargando…
Nanotechnology for Pediatric Retinoblastoma Therapy
Retinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocol...
Autores principales: | Russo, Eleonora, Spallarossa, Andrea, Tasso, Bruno, Villa, Carla, Brullo, Chiara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504930/ https://www.ncbi.nlm.nih.gov/pubmed/36145308 http://dx.doi.org/10.3390/ph15091087 |
Ejemplares similares
-
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
por: Russo, Eleonora, et al.
Publicado: (2021) -
Indole Antitumor Agents in Nanotechnology Formulations: An Overview
por: Russo, Eleonora, et al.
Publicado: (2023) -
The Development of FAK Inhibitors: A Five-Year Update
por: Spallarossa, Andrea, et al.
Publicado: (2022) -
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
por: Brullo, Chiara, et al.
Publicado: (2021) -
The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021)